X-Feed Billboard (International)
The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.
GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
Informations relatives au nombre total de droits de vote et d’actions
composant le capital
A clinical abstract on the induction results from the CoTikiS Phase 2 trial of
anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights.
Informations Relatives au Nombre Total de Droits de Vote et d’Actions
Composant le Capital
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulation immunitaire en immuno-oncologie et en immuno-inflammation, informe ses actionnaires du nombre total de droits de vote et d’actions composant son capital à la date du 31 octobre 2024 :
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences:
OSE Immunotherapeutics Announces Historic H1 2024 Results and
Provides Corporate Update
Informations relatives au nombre total de droits de vote et d’actions
composant le capital
Informations relatives au nombre total de droits de vote et d’actions
composant le capital
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Informations relatives au nombre total de droits de vote et d’actions composant le capital
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders
at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
OSE Immunotherapeutics Reports on its
2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer
by Dr Stephen Liu and Prof Benjamin Besse
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.